Galanthamine—an alkaloid first isolated from Galanthus woronowii (Amaryllidaceae)—together with donepezil and rivastigmine are the only three acetylcholinesterase inhibitor drugs approved by the Food and Drug Administration (FDA) for the palliative treatment of Alzheimer’s disease [7]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.